异丙托溴铵、沙丁胺醇合用对哮喘患儿的临床疗效、肺功能和炎症因子的影响  

The clinical efficacy of ipratropium bromide and salbutamol in the treatment of asthma in children and their effects on lung functions and inflammatory factors

作　　者：李俊稼 王琳[1] 简国江[1] 梁玉兰[2] 周太光 艾莉莉[1] LI Jun-jia;WANG Lin;JIAN Guo-jiang;LIANG Yu-lan;ZHOU Tai-guang;AI Li-li(Department of Pediatrics,Luzhou People's Hospital,Luzhou 646000,China;Department of Neonatology,Luzhou People's Hospital,Luzhou 646000,China;Department of Pediatrics,The Affiliated Hospital,Southwest Medical University,Luzhou 646000,China)

机构地区：[1]四川省泸州市人民医院儿科,四川泸州646000 [2]四川省泸州市人民医院新生儿科,四川泸州646000 [3]西南医科大学附属医院儿科,四川泸州646000

出　　处：《实用医院临床杂志》2020年第2期112-115,共4页Practical Journal of Clinical Medicine

摘　　要：目的探讨异丙托溴铵、沙丁胺醇联合应用对哮喘患儿的临床疗效、肺功能和炎症因子的影响。方法2017年4月至2019年4月我院收治的120例哮喘患儿,按入院顺序标记单双号,单号纳入单一用药组(n=60),双号纳入联合用药组(n=60),单一用药组予以沙丁胺醇治疗,联合用药组予以异丙托溴铵与沙丁胺醇联合治疗,比较两组患儿临床症状积分、症状缓解时间、肺功能、炎症因子、免疫相关转录因子表达情况以及不良反应发生情况。结果治疗后,两组气喘、胸闷、咳嗽、喉间哮鸣积分均较治疗前显著降低(P<0.05),与单一用药组比较,联合用药组下降幅度更大(P<0.05);联合用药组咳嗽缓解时间、胸闷缓解时间、气喘缓解时间、哮鸣音消失时间显著短于单一用药组,FEV1、PEF、FVC水平显著高于单一用药组,IL-4、IL-18、Tnf-α水平低于单一用药组,IL-10显著高于单一用药组(P<0.05);联合用药组BCL11B、SOCS3、T-bet的mRNA表达水平显著高于单一用药组,STAT3、GATA-3的mRNA表达水平显著低于单一用药组(P<0.05);两组不良反应发生率比较著差异无统计学意义(P>0.05)。结论异丙托溴铵与沙丁胺醇治疗小儿哮喘可明显改善患儿临床症状,缩短症状缓解时间,促进患儿肺功能恢复,减轻炎症损伤,增强患儿免疫能力。Objective To investigate the clinical efficacy of ipratropium bromide and salbutamol and their effect on lung functions and inflammatory factors in children with asthma.Methods A total of 120 children patients with asthma admitted to our hospitals from April 2017 to April 2019 were enrolled in this study.The single and double numbers were marked according to the order of admission,and the single numbers were included in single drug group(n=60),and the double numbers were included in combined drug group(n=60).The single drug group was treated with salbutamol,and the combined drug group was treated with ipratropium bromide and salbutamol.The clinical symptoms scores,symptom relief time,lung functions,inflammatory factors,immune-related transcription factors and occurrence of adverse reactions were compared between the two groups.Results After treatment,the scores of asthma,chest tightness,cough and throat wheezing in the two groups were significantly decreased when compared to before treatment(P<0.05),and the decreases in the combined drug group were greater compared with those in the single drug group(P<0.05).The cough relief time,chest tightness relief time,asthma relief time and wheezing sound disappearance time in the combined drug group were significantly shorter than those in the single drug group.The levels of FEV1,PEF and FVC in the combined drug group were significantly higher than those in the single drug group.The levels of IL-4,IL-18 and TNF-αin the combined drug group were significantly lower than those in the single drug group while the IL-10 was significantly higher than that in the single drug group(P<0.05).The mRNA expression levels of BCL11B,SOCS3,and T-bet in the combined drug group were significantly higher than those in the single drug group while the mRNA expression levels of STAT3 and GATA-3 were significantly lower than those in the single drug group(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion Ipratropium b

关 键 词：异丙托溴铵 沙丁胺醇 小儿哮喘 肺功能 炎症因子 转录因子 

分 类 号：R725.6[医药卫生—儿科]